目的：探讨改良双能量融合CT图像在肝癌TACE术后中的应用价值。方法：纳入TACE术后的26例肝癌患者，行肝脏CT常规平扫及增强三期扫描做术后评估，其中动脉期行双能扫描。使用两种后处理方法处理动脉期双能数据获得两组图像：A组图像由常规双能线性技术获得，B组图像采用新型双能量融合技术获得。以DSA为金标准，评估两种后处理方法对碘油沉积缺损区和（或）周边区强化病灶（活性区）的显示能力。结果：26例肝癌患者TACE术后复查共检出病灶60个，其中15个病灶DSA无染色，45个病灶DSA有明显肿瘤血管和染色。新型融合技术（B法）对病灶检出的敏感性为93.3%，高于常规融合技术（A法，71.1%）（χ2=8.1，P=0.004）；B法的特异性为93.3%，与A法（66.7%）无明显统计学差异（χ2=1.5，P=0.221）。且B法与DSA的一致性较优（K=0.83，P=0.000）。结论：肝癌TACE术后，新型动脉期双能融合图像技术比常规双能量融合技术能更好显示碘油沉积缺损区和（或）周边区的强化病灶。
Abstract
Objective: To evaluate the application value of a new modified dual energy image fusion in hepatocellular carcinoma after transcatheter arterial chemoembolization(TACE). Method: Twenty-six hepatocellular carcinoma(HCC) patients after post-TACE underwent normal and three phases dual-energy CT scanning(non-enhanced, arterial, portal, and delayed phases scanning) were enrolled. The arterial phase scans used the dual-energy mode. Two image sets were used to process the data: A, the weighted average image was automatically generated from a linear blending of the data. B, the new double energy fusion was obtained. DSA regarded as the gold standard, we evaluated the feasibility of two image sets, which discriminate contrast enhanced lesions from compact iodized oil accumulations, thereby helping to identify viable lesions around the HCC previously-treated by TACE. Result: DSA revealed 60 lesions in 26 patients, and 45 of them had clear tumor vessel and supply blood. The sensitivity of B(93.3%) was higher than that of A(71.1%)(χ2=8.1, P=0.004), while the specificity of B(93.3%) was insignificantly different with A(66.7%)(χ2=1.5, P=0.221). The B set has a better consistency of DSA(K=0.83, P=0.000). Conclusion: After HCCs with TACE, displaying of iodized oil accumulations and/or enhanced lesion in outside is much better in the new double energy fusion than that in conventional CT protocol.
关键词
肝肿瘤 /
体层摄影术 /
X线计算机
Key words
Liver neoplasms /
Tomography, X-ray computed
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Dong S, Ye X, Yuan Z, et al. Relationship of apparent diffusion coefficient to survival for patients with unresectable primary hepatocellular carcinoma after chemoembolization[J]. Eur J Radiol, 2012, 81(3): 472-477.
[2]Lencioni R. Chemoembolization for hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4): 503-509.
[3]Takayasu K. Transarterial chemoembolization for hepatocellular carcinoma over three decades: current progress and perspective[J]. Jpn J Clin Oncol, 2012, 42(4): 247-255.
[4]Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma[J]. AJR, 2000, 175(3): 699-704.
[5]Graser A, Johnson TR, Chandarana H, et al. Dual energy CT: preliminary observations and potential clinical applications in the abdomen[J]. Eur Radiol, 2009, 19(1): 13-23.
[6]Johnson TR, Krauss B, Sedlmair M, et al. Material differentiation by dual energy CT: initial experience[J]. Eur Radiol, 2007, 17(6): 1510-1517.
[7]Kalender WA, Perman W, Vetter J, et al. Evaluation of a prototype dual-energy computed tomographic apparatus. Ⅰ. Phantom studies[J]. Med Phys, 1986, 13(3): 334-339.
[8]Shim JH, Lee HC, Kim S, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models[J]. Radiology, 2012, 262(2): 708-718.
[9]Simons D, Kachelriess M, Schlemmer HP. Recent developments of dual-energy CT in oncology[J]. Eur Radiol, 2014, 24(4): 930-939.
[10]Agrawal MD, Pinho DF, Kulkarni NM, et al. Oncologic applications of dual-energy CT in the abdomen[J]. Radiographics, 2014, 34(3): 589-612.
[11]卫生部. 原发性肝癌诊疗规范（2011年版）[J]. 临床肿瘤学杂志，2011，16（10）：929-946.
[12]Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization(TACE) in treatment of hepatocellular carcinoma[J]. Hepatogastroenterology, 2002, 50(49): 183-187.
[13]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3): 421-430.
[14]Asayama Y, Yoshimitsu K, Nishihara Y, et al. Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation[J]. AJR, 2008, 190(1): 28-34.
[15]Kim H, Kim AY, Han JK, et al. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images[J]. Radiology, 2002, 225(3): 773-780.
[16]Kim SH, Lee WJ, Lim HK, et al. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography[J]. J Comput Assist Tomogr, 2007, 31(2): 198-203.
[17]Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings[J]. Radiology, 1992, 182(3): 709-713.
[18]Lee J, Jeong WK, Kim Y, et al. Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging[J]. Eur J Radiol, 2013, 82(4): 569-576.
